SmithKline returns rights to Coulter

SmithKline Beecham (LSE:SB; SBH) returned development and commercialization rights to CLTR's Bexxar cancer therapy outside the U.S. As a result, CLTR will be eligible for less than the $76 million in milestones

Read the full 326 word article

How to gain access

Continue reading with a
two-week free trial.